PNC-27: A Novel Anticancer Peptide Targeting Membrane HDM-2
Discover the selective power of PNC-27 in inducing cancer cell necrosis with minimal impact on healthy cells.
Get a Quote & SampleProduct Core Value
PNC-27 Peptide
PNC-27 is a groundbreaking anticancer peptide that exhibits remarkable selectivity by targeting the HDM-2 protein predominantly found on the membranes of cancer cells. This targeted interaction triggers the formation of transmembrane pores, leading to cancer cell necrosis without affecting normal cells. Its unique mechanism of action makes it a promising candidate for novel cancer treatments.
- Explore the unique PNC-27 mechanism of action, focusing on its selective binding to membrane-bound HDM-2 for targeted cancer cell destruction.
- Investigate the potential of peptide cancer therapy, highlighting how PNC-27 offers a novel approach compared to traditional treatments.
- Understand the concept of cancer cell necrosis induced by PNC-27, a key differentiator from apoptosis-driven treatments.
- Learn about the intricate PNC-27 synthesis process, ensuring high purity and efficacy for research and therapeutic applications.
Key Advantages
Targeted Action
PNC-27 demonstrates high precision in targeting HDM-2 cancer cells, ensuring that therapeutic effects are concentrated where they are most needed.
Selective Cytotoxicity
This peptide offers PNC-27 selective cytotoxicity, meaning it effectively eliminates cancerous cells while preserving the integrity of healthy tissues.
P53-Independent Pathway
The efficacy of PNC-27 in PNC-27 anticancer peptide research is further enhanced by its ability to operate via a P53-independent pathway, broadening its applicability.
Key Applications
Cancer Research
PNC-27 serves as a critical tool in cancer research, aiding scientists in understanding targeted cell death mechanisms and developing new treatment strategies.
Anticancer Therapy Development
As a leading candidate in peptide-based anticancer therapies, PNC-27 is being explored for its therapeutic potential in clinical settings.
Leukemia Treatment Innovation
The unique properties of PNC-27 offer new hope for leukemia treatment, targeting cancerous cells with unprecedented specificity.
Biotechnology Advancements
The development of PNC-27 showcases advancements in biotechnology in cancer research, paving the way for future peptide-based pharmaceuticals.
Related Technical Articles & Resources
Why Choose Us?
Leverage our expertise and state-of-the-art infrastructure to accelerate your journey from discovery to commercial success.
Global Experience
With 20 years of R&D, manufacturing, and sales experience, we proudly serve clients across 60 countries and regions worldwide.
Advanced Facilities
Our in-house R&D laboratory, pilot platform, and large-scale production workshop are equipped to meet the audit requirements of global customers.
Seamless Scalability
We facilitate a perfect transition from small-scale lab requirements (grams) to full commercialization (hundreds of tons).